Background and Purpose—The use of vitamin K antagonists (VKAs), the cornerstone
treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Background and Purpose—There are limited real-world data comparing the effectiveness
and safety of non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in Asians …

The current manuscript is the second update of the original Practical Guide, published in
2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Non-vitamin K antagonist oral anticoagulants (NOACs) have changed the landscape for
stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, more …

The current manuscript is an update of the original Practical Guide, published in June 2013
[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart …

Background Following their introduction, the non-vitamin K antagonist oral anticoagulants
(NOACs) are increasingly prescribed in Asia for stroke prevention in patients with non …